Study: Better understanding is key to beating diabetes
September 12th 2021EURETINA
In a presentation at the EURETINA 2021 Virtual Conference, Tunde Peto, MD, PhD, pointed out that while complications associated with diabetes develop over a long period, ophthalmologists today have an excellent understanding of diabetes-related eye changes.
Brolucizumab injection offers improved vision in neovascular age-related macular degeneration
September 11th 2021EURETINA
In a presentation at the EURETINA 2021 Virtual Congress, Cristina Cristian, MD, noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.
Managing retinal folds, role of anterior vitreous in retinal detachments
September 11th 2021EURETINA
Grazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.
Gene-independent therapeutic strategies for retinal degeneration include optogenetic therapy
September 10th 2021EURETINA
During a presentation at the EURETINA 2021 Virtual Congress, José-Alain Sahel, MD, explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.
Facing the challenges of treating peripheral hemorrhagic polypoidal choroidal vasculopathy
September 9th 2021EURETINA
Treating the disease can be a challenge, and at the EURETINA 2021 Virtual Congress, Chekitaan Singh, MD, discussed a case study detailing the care of a patient who had already lost vision in one eye from a similar issue.
Foveal morphologic changes in LCA sparked by gene therapy
May 10th 2021ARVO
In a presentation at ARVO, Friederike Kortuem, MD, MSc, explains that treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.
Analyzing clinical results of dexamethasone implant effect on macular thickness
May 5th 2021ARVO
Daniel F. Kiernan, MD, discusses key findings of a clinical study analyzing the effect of dexamethasone intracameral drug-delivery suspension on macular thickness based on OCT testing following vitreoretinal surgery.
Wet AMD treatment burden eased by nonviral gene therapy
May 3rd 2021ARVO
EYS809, a non-viral gene therapy sustained drug-delivery product that delivers anti-vascular endothelial growth factor to the eye, may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients diagnosed with wet age-related macular degeneration.